Zentalis Pharmaceuticals (NASDAQ:ZNTL) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note published on Thursday, MarketBeat reports. The firm issued a buy rating and a $11.00 price target on the stock.

Several other research analysts also recently weighed in on ZNTL. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. Wall Street Zen upgraded Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 31st. Mizuho assumed coverage on Zentalis Pharmaceuticals in a report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Finally, Guggenheim boosted their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a report on Friday, April 10th. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $6.75.

Zentalis Pharmaceuticals Stock Performance

Shares of NASDAQ:ZNTL opened at $4.33 on Thursday. The stock has a market capitalization of $308.25 million, a price-to-earnings ratio of -2.50 and a beta of 1.92. The stock’s 50-day simple moving average is $4.15 and its two-hundred day simple moving average is $3.47. Zentalis Pharmaceuticals has a 52-week low of $1.21 and a 52-week high of $6.95.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.01). As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -1.83 earnings per share for the current fiscal year.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of ZNTL. Sivia Capital Partners LLC purchased a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $27,000. CTC Alternative Strategies Ltd. bought a new stake in Zentalis Pharmaceuticals during the first quarter valued at about $29,000. Qube Research & Technologies Ltd bought a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $37,000. Voleon Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at about $41,000. Finally, State of Wyoming bought a new position in shares of Zentalis Pharmaceuticals in the first quarter worth about $67,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.